IFNG and neoplasm: A new fusion protein comprising anti-PD-L1 that is genetically fused to tumoricidal protein tumor necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL) bound to PD-L1 expressed on tumor or myeloid effector cells such as monocytes, macrophages, and dendritic cells, causes secretion of IFN-γ by activating T cells.